Charleen specialises in life sciences intellectual property litigation and advising clients in the life sciences sector on regulatory issues. She is a skilled commercial litigator, with extensive experience in complex, multi-jurisdictional patent and trade mark disputes. Her patent litigation experience ranges from medical devices to pharmaceuticals and biologics. In addition, Charleen has a particular interest in complex medical device product liability claims.
In the areas of pharmaceuticals, biotechnology and medical devices, Charleen advises on every phase of a product’s life cycle from product development, clinical trials, data exclusivity, regulatory approval to commercialisation and product safety/recall/liability.
Charleen is ranked as a “Next Generation Partner” by the Legal 500 EMEA 2022 for Intellectual Property and Life Sciences, as an IAM Patent 1000 Silver Individual and as a “Patent Star 2023” by Managing Intellectual Property IP Stars.
Recent significant cases include representing:
- Eli Lilly in Commercial Court proceedings seeking revocation of a Novartis patent and in the defence of infringement proceedings (including a competition law counterclaim against Novartis) with respect to Lilly’s product, Taltz®/ixekizumab for the treatment of psoriasis.
- Eli Lilly in complex multi-jurisdictional patent revocation proceedings against Eisai R&D Management Co (relating to the treatment of Alzheimer’s disease).
- AstraZeneca in its appeal to the Commercial Court relating to the Controller of Intellectual Property’s decision regarding the grant of a supplementary protection certificate.
- Genentech Inc in Commercial Court proceedings against Amgen relating to Amgen’s product Mvasi®, a biosimilar of Genentech’s leading cancer drug Avastin®.
- Boehringer Ingelheim in the defence of two sets of Commercial Court proceedings brought by Teva Pharmaceuticals, seeking the revocation of a patent and a supplementary protection certificate in relation to a respiratory product.
- GSK in Commercial Court patent infringement proceedings against Pfizer (relating to GSK’s MenB vaccine, BEXERO).
- GSK in its trade mark and passing off action against Rowex Limited involving the Seretide Inhaler.
- Boston Scientific in the defence of Commercial Court patent infringement proceedings relating to coronary stents brought by OrbusNeich and in a counterclaim for invalidity of the patents at issue.
Ranking & Recommendations
Knowledge
Charleen is a Partner in William Fry’s Litigation & Investigations Department and a member of its Life Sciences Group, specialising in intellectual property and regulatory law.
Charleen is a skilled commercial litigator, with extensive experience in complex, multi-jurisdictional intellectual property disputes. Her patent litigation experience ranges from pharmaceutical and biologics to a wide range of technologies including hi-tech and medical devices.
She advises in the areas of pharmaceuticals, biotechnology and medical devices, covering every phase of a product’s life cycle from product development, clinical trials, data exclusivity, regulatory approval to commercialisation and product safety/recall/liability.
Recent significant cases include representing:
- Genentech Inc in Commercial Court proceedings against Amgen relating to Amgen’s product Mvasi®, a biosimilar of Genentech’s leading cancer drug Avastin®.
- Eli Lilly in complex multi-jurisdictional patent revocation proceedings against Eisai R&D Management Co (relating to the treatment of Alzheimer’s disease).
- Boehringer Ingelheim in the defence of patent and SPC revocation proceedings brought by Teva Pharmaceuticals.
- GlaxoSmithKline (“GSK”) in Commercial Court patent infringement proceedings against Pfizer (relating to GSK’s MenB vaccine, BEXERO).
- GSK in its trade mark and passing off action against Rowex Limited involving the Seretide Inhaler, one of the all-time best-selling prescription drugs.
- BSA
Charleen is ranked by WTR 1000 2022: The World’s Leading Trademark Professionals by WTR 1000 2022 and is also ranked as a “Notable practitioner” and ‘Rising Star’ (Managing Intellectual Property IP Stars 2022 and 2020).